Myelodysplastic syndrome classification: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(37 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myelodysplastic syndrome}}
{{Myelodysplastic syndrome}}
{{CMG}}
{{CMG}};{{AE}} {{NM}}
 
==Overview==
==Overview==
The myelodysplastic syndrome may be classified into several subtypes based on the [[French-American-British classification|French-American-British (FAB) classification]] and the[[World Health Organization]] (WHO) classification methods.


==Classification==
==Classification==
===French-American-British (FAB) classification===
===French-American-British (FAB) Classification===
In 1974 and 1975 a group of pathologists from France, the United States, and Britain met and deliberated and derived the first widely used classification of these diseases.  This [[French-American-British classification | French-American-British (FAB) classification]] was published in 1976 and revised in 1982. Cases were classified into 5 categories: ([[ICD-O]] codes are provided where available)
*Myelodysplastic syndrome may be classified according to the [[French-American-British classification|French-American-British classification]] into five groups: Refractory [[anemia]], refractory anemia with ring sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
*The table below lists [[French-American-British classification|FAB]] classification for myelodysplastic syndrome:<ref name="cancergov2">Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref>
 
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
| valign="top" |
|+
! style="background: #4479BA; width: 250px; color: #FFFFFF;" |'''Name'''
 
! style="background: #4479BA; width: 600px; color: #FFFFFF;" |'''Description'''


* ({{ICDO|9980|3}}) '''Refractory [[anemia]]''' (RA) - characterized by less than 5% primitive blood cells ([[myeloblasts]]) in the bone marrow and pathological abnormalities primarily seen in red cell precursors;
|-
* ({{ICDO|9982|3}}) '''Refractory anemia with ringed sideroblasts''' (RARS) - also characterized by less than 5% myeloblasts in the bone marrow, but distinguished by the presence of 15% or greater red cell precursors in the marrow being abnormal iron-stuffed cells called "ringed sideroblasts";
* ({{ICDO|9983|3}}) '''Refractory anemia with excess blasts''' (RAEB) - characterized by 5-19% myeloblasts in the marrow;
* ({{ICDO|9984|3}}) '''Refractory anemia with excess blasts in transformation''' (RAEB-T) - characterized by 20-29% myeloblasts in the marrow (30% blasts is defined as acute myeloid leukemia);
* ({{ICDO|9945|3}}) '''Chronic myelomonocytic leukemia''' (CMML) - not to be confused with [[chronic myelogenous leukemia]] or CML - characterized by less than 20% myeloblasts in the bone marrow and greater than 1000 * 10<sup>9</sup>/uL monocytes (a type of white blood cell) circulating in the peripheral blood.


A table comparing these is available from the [http://www.clevelandclinicmeded.com/diseasemanagement/hematology/myelo/table1.htm Cleveland Clinic].
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Refractory anemia'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:* Less than 5% primitive blood cells (myeloblasts) in the bone marrow and pathological abnormalities primarily seen in red blood cell precursors.


The best prognosis is seen with refractory anemia with ringed sideroblasts and refractory anemia, where some non-transplant patients live more than a decade (the average is on the order of 3-5 years, although long term remission is possible if a bone marrow transplant is successful); the worst outlook is with RAEB-T, where the mean life expectancy is less than 1 year. Leukemic transformation occurs in about 10-17% of patients with RA/RARS; it is approximately 40-60% for patients with RAEB. The others die of complications of low blood count or unrelated disease. 
|-


The FAB classification was used by pathologists and clinicians for almost 20 years.  By the early 21st century the WHO classification had replaced it.
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Refractory anemia with ring sideroblasts (RARS)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:* Less than 5% myeloblasts in the bone marrow, but distinguished by the presence of ringed sideroblasts which may compose greater than 15% of red blood cell precursor in the marrow.


===WHO classification===
|-
In the late 1990s a group of pathologists and clinicians working under the World Health Organization (WHO) modified this classification, introducing several new disease categories and eliminating others.


One new category was refractory cytopenia with multilineage dysplasia (RCMD), which includes patients with pathological changes not restricted to red cells (i.e., prominent white cell precursor and platelet precursor (megakaryocyte) dysplasia.  See below for morphologic definitions of dysplasia.
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Refractory anemia with excess blasts (RAEB)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:* 5-20% myeloblasts in the marrow


The list of dysplastic syndromes under the new WHO system includes:
|-
# Refractory anemia (RA)
# Refractory anemia with ringed sideroblasts (RARS)
# Refractory cytopenia with multilineage dysplasia (RCMD)
# Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)
# Refractory anemia with excess blasts I and II
# [[5q- syndrome]]
# Myelodysplasia unclassifiable (seen in those cases of megakaryocyte dysplasia with fibrosis and others)


RAEB was divided into *RAEB-I (5-10% blasts) and RAEB-II (11-19%) blasts, which has a poorer prognosis than RAEB-I.  Auer rods may be seen in RAEB-II which may be difficult to distinguish from acute myeloid leukemia.  The presence of 20% or more blasts denotes the diagnosis of AML.  (In the new WHO classification RAEB-T no longer exists). 
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Refractory anemia with excess blasts in transformation (RAEB-T)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*21-30% myeloblasts in the marrow (>30% blasts is defined as acute myeloid leukemia)


5q- syndrome, typically seen in older women was added to the classification.  The diagnosis of 5q minus syndrome requires that 5q minus MUST be an isolated abnormality.  Clinical manifestations include a tendency towards a hypercellular bone marrow, macrocytosis/RA, normal or high platelet counts and hypolobulated megakaryocytes.  It carries a good prognosis, with a median survival > 5 years, a low risk of AML and a benign course.  14(RPS4) is the underlying genetic defect of  5q minus syndrome.  Haploinsufficiency of the ribosomal gene 14(RPS4)occurs here; it is required for the maturation of the 40s ribosomal subunit and it maps to the deleted region on 5q minus.  67% of patients with 5q minus achieve transfusion independence with the administration of Lenalidomide.  Lenalidomide in 5q minus causes a response by decreasing Cdc25c and PP2A mRNA expression.  Lenalidomide has such high clinical activity for this type of MDS that it is almost comparable to teh track record of imatinib in CML. 
|-


CMML was removed from the myelodysplastic syndromes and put in a new category of myelodysplastic-myeloproliferative overlap syndromes. Not all physicians concur with this reclassification.  This is because the underlying pathology of the diseases is not well understood. It is difficult to classify things that are not well understood.
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Chronic myelomonocytic leukemia (CMML)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*Less than 20% myeloblasts in the bone marrow and greater than 1*109/L monocytes in peripheral blood
 
|}
===WHO Classification===
*The table below lists World Health Organization classification for myelodysplastic syndrome:<ref name="cancergov2">Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref><ref name="pmid29085786">{{cite journal |vauthors=Hong M, He G |title=The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes |journal=J Transl Int Med |volume=5 |issue=3 |pages=139–143 |date=September 2017 |pmid=29085786 |pmc=5655460 |doi=10.1515/jtim-2017-0002 |url=}}</ref><ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref>
 
{| style="border: 0px; font-size: 90%; margin: 3px; width: 800px"
 
|+
! colspan="1" rowspan="1" style="background: #4479BA; width: 200px; color: #FFFFFF;" |2008
 
! colspan="1" rowspan="1" style="background: #4479BA; width: 200px; color: #FFFFFF;" |2016
 
|-
 
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Refractory cytopenia with unilineage dysplasia (RCUD)
*    Refractory anemia (RA)
*    Refractory neutropenia (RN)
*    Refractory thrombocytopenia (RT)
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with single lineage dysplasia (MDS-SLD)
|-
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Refractory anemia with ring sideroblasts (RARS)
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with ring sideroblasts (MDS-RS)
* MDS-RS-SLD
* MDS-RS-MLD
|-
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Refractory cytopenias with multilineage dysplasia
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with multilineage dysplasia (MDS-MLD)
|-
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Refractory anemia with excess blasts (RAEB)
*RAEB-1
*RAEB-2
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with excess blasts (MDS-EB)
*MDS-EB-1
*MDS-EB-2
|-
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with isolated del(5q)
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS with isolated del(5q)
|-
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS, unclassifiable (MDS-U)
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |MDS, unclassifiable (MDS-U)
|-
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Refractory cytopenia of childhood (provisional)
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #F5F5F5;" align="left" |Refractory cytopenia of childhood (provisional)
|}


==References==
==References==
Line 46: Line 91:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Oncology]]
[[Category:Hematology]]
[[Category:Hematology]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Latest revision as of 20:26, 7 March 2019

Myelodysplastic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelodysplastic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelodysplastic syndrome classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelodysplastic syndrome classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelodysplastic syndrome classification

CDC on Myelodysplastic syndrome classification

Myelodysplastic syndrome classification in the news

Blogs on Myelodysplastic syndrome classification

Directions to Hospitals Treating Myelodysplastic syndrome

Risk calculators and risk factors for Myelodysplastic syndrome classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

Overview

The myelodysplastic syndrome may be classified into several subtypes based on the French-American-British (FAB) classification and theWorld Health Organization (WHO) classification methods.

Classification

French-American-British (FAB) Classification

  • Myelodysplastic syndrome may be classified according to the French-American-British classification into five groups: Refractory anemia, refractory anemia with ring sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
  • The table below lists FAB classification for myelodysplastic syndrome:[1]
Name Description
Refractory anemia
  • Less than 5% primitive blood cells (myeloblasts) in the bone marrow and pathological abnormalities primarily seen in red blood cell precursors.
Refractory anemia with ring sideroblasts (RARS)
  • Less than 5% myeloblasts in the bone marrow, but distinguished by the presence of ringed sideroblasts which may compose greater than 15% of red blood cell precursor in the marrow.
Refractory anemia with excess blasts (RAEB)
  • 5-20% myeloblasts in the marrow
Refractory anemia with excess blasts in transformation (RAEB-T)
  • 21-30% myeloblasts in the marrow (>30% blasts is defined as acute myeloid leukemia)
Chronic myelomonocytic leukemia (CMML)
  • Less than 20% myeloblasts in the bone marrow and greater than 1*109/L monocytes in peripheral blood

WHO Classification

  • The table below lists World Health Organization classification for myelodysplastic syndrome:[1][2][3]
2008 2016
Refractory cytopenia with unilineage dysplasia (RCUD)
  •    Refractory anemia (RA)
  •    Refractory neutropenia (RN)
  •    Refractory thrombocytopenia (RT)
 MDS with single lineage dysplasia (MDS-SLD)
Refractory anemia with ring sideroblasts (RARS) MDS with ring sideroblasts (MDS-RS)
  • MDS-RS-SLD
  • MDS-RS-MLD
Refractory cytopenias with multilineage dysplasia MDS with multilineage dysplasia (MDS-MLD)
Refractory anemia with excess blasts (RAEB)
  • RAEB-1
  • RAEB-2
 MDS with excess blasts (MDS-EB)
  • MDS-EB-1
  • MDS-EB-2
MDS with isolated del(5q) MDS with isolated del(5q)
MDS, unclassifiable (MDS-U) MDS, unclassifiable (MDS-U)
Refractory cytopenia of childhood (provisional) Refractory cytopenia of childhood (provisional)

References

  1. ↑ 1.0 1.1 Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015
  2. ↑ Hong M, He G (September 2017). "The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes". J Transl Int Med. 5 (3): 139–143. doi:10.1515/jtim-2017-0002. PMC 5655460. PMID 29085786.
  3. ↑ Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Myelodysplastic_syndrome_classification&oldid=1557243"